JPS6045525A - 抗リウマチ剤 - Google Patents
抗リウマチ剤Info
- Publication number
- JPS6045525A JPS6045525A JP58147232A JP14723283A JPS6045525A JP S6045525 A JPS6045525 A JP S6045525A JP 58147232 A JP58147232 A JP 58147232A JP 14723283 A JP14723283 A JP 14723283A JP S6045525 A JPS6045525 A JP S6045525A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- agent
- krestin
- protein polysaccharide
- antirheumatic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003435 antirheumatic agent Substances 0.000 title claims abstract description 16
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 20
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 20
- 150000004676 glycans Chemical class 0.000 claims abstract description 18
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 18
- 239000005017 polysaccharide Substances 0.000 claims abstract description 18
- 108010001062 polysaccharide-K Proteins 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 238000005199 ultracentrifugation Methods 0.000 claims abstract 2
- 241000221198 Basidiomycota Species 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000012670 alkaline solution Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 238000000691 measurement method Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 239000002246 antineoplastic agent Substances 0.000 abstract description 3
- 231100000053 low toxicity Toxicity 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 208000009386 Experimental Arthritis Diseases 0.000 abstract 2
- 241000222355 Trametes versicolor Species 0.000 abstract 2
- 239000003513 alkali Substances 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 14
- 241000700159 Rattus Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 240000000249 Morus alba Species 0.000 description 2
- 235000008708 Morus alba Nutrition 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- FYGDTMLNYKFZSV-WFYNLLPOSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,3s,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-WFYNLLPOSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- QZHXKQKKEBXYRG-UHFFFAOYSA-N 4-n-(4-aminophenyl)benzene-1,4-diamine Chemical compound C1=CC(N)=CC=C1NC1=CC=C(N)C=C1 QZHXKQKKEBXYRG-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 240000003473 Grevillea banksii Species 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002905 effect on arthritis Effects 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- -1 valine and leucine Chemical class 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Priority Applications (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58147232A JPS6045525A (ja) | 1983-08-11 | 1983-08-11 | 抗リウマチ剤 |
| DE3448154A DE3448154C2 (enrdf_load_stackoverflow) | 1983-08-11 | 1984-08-10 | |
| DE3448150A DE3448150C2 (enrdf_load_stackoverflow) | 1983-08-11 | 1984-08-10 | |
| DE19843429551 DE3429551A1 (de) | 1983-08-11 | 1984-08-10 | Pharmazeutische zubereitung, die ein glycoprotein enthaelt |
| DE3448153A DE3448153C2 (enrdf_load_stackoverflow) | 1983-08-11 | 1984-08-10 | |
| DE3448151A DE3448151C2 (enrdf_load_stackoverflow) | 1983-08-11 | 1984-08-10 | |
| DE3448149A DE3448149C2 (enrdf_load_stackoverflow) | 1983-08-11 | 1984-08-10 | |
| DE3448152A DE3448152C2 (enrdf_load_stackoverflow) | 1983-08-11 | 1984-08-10 | |
| DE3448155A DE3448155C2 (enrdf_load_stackoverflow) | 1983-08-11 | 1984-08-10 | |
| DE3448148A DE3448148C2 (enrdf_load_stackoverflow) | 1983-08-11 | 1984-08-10 | |
| DE3448144A DE3448144C2 (enrdf_load_stackoverflow) | 1983-08-11 | 1984-08-10 | |
| DE3448145A DE3448145C2 (enrdf_load_stackoverflow) | 1983-08-11 | 1984-08-10 | |
| US06/898,900 US4820689A (en) | 1983-08-11 | 1986-08-22 | Pharmaceutical composition containing a glycoprotein |
| US07/285,664 US5008243A (en) | 1983-08-11 | 1988-12-16 | Pharmaceutical composition containing a glycoprotein |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58147232A JPS6045525A (ja) | 1983-08-11 | 1983-08-11 | 抗リウマチ剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6045525A true JPS6045525A (ja) | 1985-03-12 |
| JPH0326173B2 JPH0326173B2 (enrdf_load_stackoverflow) | 1991-04-10 |
Family
ID=15425557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58147232A Granted JPS6045525A (ja) | 1983-08-11 | 1983-08-11 | 抗リウマチ剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6045525A (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5693610A (en) * | 1994-08-25 | 1997-12-02 | Kureha Chemical Industry Co., Ltd. | Binding agent for growth factor |
-
1983
- 1983-08-11 JP JP58147232A patent/JPS6045525A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5693610A (en) * | 1994-08-25 | 1997-12-02 | Kureha Chemical Industry Co., Ltd. | Binding agent for growth factor |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0326173B2 (enrdf_load_stackoverflow) | 1991-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Darby et al. | Treatment of sprue with synthetic L. casei factor (folic acid, vitamin M). | |
| EP0251134A2 (en) | Compositions for preventing graft rejection | |
| JPH11500119A (ja) | インターロイキン１２を用いる脈管形成の阻害 | |
| US6726932B2 (en) | Fatty acid-containing composition | |
| KR920002935B1 (ko) | 맥관 형성 저해제 | |
| JPS6045525A (ja) | 抗リウマチ剤 | |
| JPH0475205B2 (enrdf_load_stackoverflow) | ||
| JP4195107B2 (ja) | ストレス蛋白質発現増強剤 | |
| EP0295962B1 (en) | Protein-polysaccharide for treating retroviral infections | |
| JPH04275231A (ja) | 事故結果として多外傷を有する危険な患者に於て、臓器拒絶の予防及び（又は）処置に、スーパーオキシドジスムターゼを使用する方法 | |
| HU185315B (en) | Siliconpolymer compositions for treating textile materials | |
| Klein et al. | Investigations on the nature of haemopoietin, the anti-anaemic substance in hog's stomach: The production of a thermostable haemopoietically active substance similar to or identical with the anti-anaemic principle of liver by the action of the thermolabile haemopoietin on beef | |
| CN114796198A (zh) | 金粟兰内酯b在制备nlrp3炎症小体抑制剂中的应用 | |
| JPS6045528A (ja) | 虚血性脳疾患改善剤 | |
| JPH0361651B2 (enrdf_load_stackoverflow) | ||
| US6475520B1 (en) | Pharmaceutical composition with low toxicity for anti-inflammation and anti-exudation | |
| Markus et al. | Treatment of chronic lead-poisoning with calcium disodium versenate | |
| JPS6045532A (ja) | 血糖降下剤 | |
| JPS6045530A (ja) | ネフロ−ゼ症候群改善剤 | |
| JP3769045B2 (ja) | 抗炎症剤 | |
| KR20010040752A (ko) | 에이즈 치료제 | |
| JPS6045527A (ja) | 血圧降下剤 | |
| JPS6045524A (ja) | 抗炎症剤 | |
| JPS6045526A (ja) | 虚血性心疾患改善剤 | |
| JPS6045523A (ja) | 解熱鎮痛剤 |